Briefing
FDA Oncologic Drugs Advisory Committee vote on MRD as an accelerated-approval endpoint in multiple myeloma
ODAC voted Yes 12, No 0, Abstain 0 on: 'Does the evidence support the use of MRD as an accelerated approval endpoint in MM clinical trials?' Committee discussion supported use in both newly diagnosed and relapsed/refractory settings, with 9-month, 12-month, and MRD-negative CR at any time considered acceptable assessment timepoints. Minutes approved July 2, 2024.
- Design: regulatory